Dr. Howard Colman discusses the availability of lomustine for the treatment of glioblastoma multiforme (GBM) in light of the drug's recent withdrawal from Medicare Part D coverage.
Show references: https://journals.lww.com/neurotodayonline/Fulltext/2021/09160/A_Glioblastoma_Drug_Is_Abruptly_Withdrawn_from.6.aspx
